GENERAL COMMENTS
The work is well set and the results that can be obtained can be interesting.
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GENERAL COMMENTS
This is a case control study to assess metabolic syndrome and cancer risk. It depends on public health database of Catalonia. Study plans to identify cancer patients from the database and evaluate their metabolic syndrome history from the database. However there are major concerns to be addressed. Hyperinsulinemia is a factor which increases cancer risk and it should be mentioned. There ought to be an explanation for choosing 102/88 cm as waist circumference cut-off value while for Europeans cut-off value is generally 94/80 cm. To define cut off values the correct symbol to use would be "≥" instead of ">". Authors have used an older reference to define metabolic syndrome. There is a consensus report which should be preferred (Alberti, K. G. M. M., et al. "Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity." Circulation 120. 16 (2009): 1640-1645.) .
A study, which investigates whether metabolic syndrome increases cancer risk more than its parameters, should focus on the effect of "abdominal obesity" not "obesity". If waist circumference is not available for all of the subjects, defining metabolic syndrome with body mass index would be a major limitation for the study because it is known that there are crucial differences between the medical effects of excess visceral adipose tissue and subcutaneous adipose tissue. Furthermore body mass index is associated not only with adipose tissue also with muscle tissue and the effect of muscle tissue on health is opposite of visceral adipose mass. These restrictions should be mentioned by the authors and if possible a protocol change should be considered. First diagnosis would indicate the first time the condition is recorded not exposed. Metabolic syndrome could have started long ago and because it is unknown when the condition started it should be interpreted accordingly. In this context exposure time might cause controversy in results and "immortal/immeasurable time bias" risk should be considered and discussed.
VERSION 1 -AUTHOR RESPONSE
Reviewer ( This is a case control study to assess metabolic syndrome and cancer risk. It depends on public health database of Catalonia. Study plans to identify cancer patients from the database and evaluate their metabolic syndrome history from the database. However there are major concerns to be addressed.
1)Hyperinsulinemia is a factor which increases cancer risk and it should be mentioned.
In cases of insulin resistance, the pancreas compensates this resistance with insulin extrasecretion. Hiperinsulinemia is not considered a component of metabolic syndrome itself but can be coexisting in those cases with high level of glicemia. We add a comment in the page 6 of the introduction section.
2)There ought to be an explanation for choosing 102/88 cm as waist circumference cut-off value while for Europeans cut-off value is generally 94/80 cm. To define cut off values the correct symbol to use would be "≥" instead of ">".
As it is mentioned in the publication by Alberti el al., there are different cut-off values according to nationality. We selected the cut off proposed by European Cardiovascular Societies (≥102/88).
Europid recommendations are applied to men in the Middle or Easten Mediterranean region. We maintain 102/88 since Catalonia is placed in West Mediterranean region (page 9).
3)Authors have used an older reference to define metabolic syndrome. There is a consensus report which should be preferred (Alberti, K. G. M. M., et al. "Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity." Circulation 120. 16 (2009): 1640-1645.) .
According the suggestion provided by the reviewer we adapt the information related to metabolic syndrome and we include the new values in page 9 of the methodology section. 4)A study, which investigates whether metabolic syndrome increases cancer risk more than its parameters, should focus on the effect of "abdominal obesity" not "obesity". If waist circumference is not available for all of the subjects, defining metabolic syndrome with body mass index would be a major limitation for the study because it is known that there are crucial differences between the medical effects of excess visceral adipose tissue and subcutaneous adipose tissue. Furthermore body mass index is associated not only with adipose tissue also with muscle tissue and the effect of muscle tissue on health is opposite of visceral adipose mass. These restrictions should be mentioned by the authors and if possible a protocol change should be considered.
We agree with the reviewer , but waist circumferences is only available in a few subjects. This is a restriction of the electronic database. According WHO definition (Grundy SM, Brewer HB, Jr., Cleeman JI, Smith SC, Jr., Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004; 109:433-8) body mass index (BMI)> 30 kg / m2 can be considered as an alternative.
We clarify this aspect in page 10 and 11 and we will add a sensitivity analysis restricted to those patients to whom waist circumference has been recorded. 5)First diagnosis would indicate the first time the condition is recorded not exposed. Metabolic syndrome could have started long ago and because it is unknown when the condition started it should be interpreted accordingly. In this context exposure time might cause controversy in results and "immortal/immeasurable time bias" risk should be considered and discussed.
We appreciate the comment of the reviewer. It is true for those cases where the date of registration is in 2006. If in that year there is a patient who has three parameters, the date indicated will be registration and not exposure. It also happens when one or two parameters have been recorded. This aspect is especially relevant for the objective 2, where the time between exposure and cancer will be calculated.
We will carry out an analysis with those patients who in 2006 have not registered any parameter and the first registration is in 2007. We clarify it in the page 10 and 11. 
GENERAL COMMENTS
Thank you for corrections and clarifications.
